HRP20110196T1 - 3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije - Google Patents
3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije Download PDFInfo
- Publication number
- HRP20110196T1 HRP20110196T1 HR20110196T HRP20110196T HRP20110196T1 HR P20110196 T1 HRP20110196 T1 HR P20110196T1 HR 20110196 T HR20110196 T HR 20110196T HR P20110196 T HRP20110196 T HR P20110196T HR P20110196 T1 HRP20110196 T1 HR P20110196T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorders
- pharmaceutical preparation
- group
- treatment
- preparation according
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- -1 3, 5-disubstituted phenyl-piperidines Chemical class 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 230000005062 synaptic transmission Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 11
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- PHRDGRSMZPOCAB-UHFFFAOYSA-N 1-ethyl-4-(3-fluoro-5-methylsulfonylphenyl)piperidine Chemical group C1CN(CC)CCC1C1=CC(F)=CC(S(C)(=O)=O)=C1 PHRDGRSMZPOCAB-UHFFFAOYSA-N 0.000 claims 2
- PKMDJEDRPXYECK-UHFFFAOYSA-N 4-(3-fluoro-5-methylsulfonylphenyl)-1-propylpiperidine Chemical group C1CN(CCC)CCC1C1=CC(F)=CC(S(C)(=O)=O)=C1 PKMDJEDRPXYECK-UHFFFAOYSA-N 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 230000000642 iatrogenic effect Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020852 Hypertonia Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 231100000317 environmental toxin Toxicity 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 230000007659 motor function Effects 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Spoj Formule 1, naznačen time, što je: R izabran iz grupe koja sadrži C1-C3 alkile i alil; i njegove farmaceutski prihvatljive soli. Patent sadrži još 18 patentnih zahtjeva.
Claims (19)
1. Spoj Formule 1, naznačen time, što je:
[image]
R izabran iz grupe koja sadrži C1-C3 alkile i alil;
i njegove farmaceutski prihvatljive soli.
2. Spoj prema zahtjevu 1, naznačen time, što je R izabran iz grupe koja sadrži n-propil i etil.
3. Spoj prema zahtjevu 1, naznačen time, što je 1-etil-4-[3-fluoro-5-(metilsulfonil)fenil]piperidin; ili njegova farmaceutski prihvatljiva sol.
4. Spoj prema zahtjevu 1, naznačen time, što je 1-etil-4-[3-fluoro-5-(metilsulfonil)fenil]piperidin sol hidroklorične kiseline.
5. Spoj prema zahtjevu 1, naznačen time, što je 4-[3-fluoro-5-(metilsulfonil)fenil]-1-propilpiperidin; ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema zahtjevu 1, naznačen time, što je 4-[3-fluoro-5-(metilsulfonil)fenil]-1-propilpiperidin sol hidroklorične kiseline
7. Spoj prema zahtjevu 1, naznačen time, što je 1-alil-4-[3-fluoro-5-(metilsulfonil)fenil]piperidin; ili njegova farmaceutski prihvatljiva sol.
8. Farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem zahtjevu 1-7 i jedan ili više farmaceutski prihvatljiv nosač ili razrjeđivač.
9. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje poremećaja središnjeg živčanog sustava.
10. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje poremećaja kretanja odabranih iz skupine koja se sastoji od Parkinsonove bolesti, parkinsonizma, diskinezije (uključujući L-DOPA induciran diskinezijom), distonije, tikova, drhtanja i Huntingtonove bolesti.
11. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje stanja odabranih iz skupine koja se sastoji od jatrogene i nejatrogene psihoze i halucinacija.
12. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje stanja odabranih iz skupine koja se sastoji od shizofrenije i shizofreničnih poremećaja i bipolarnog poremećaja.
13. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje stanja odabranih iz skupine koja se sastoji od poremećaja raspoloženja i anksioznosti, depresije i opsesivno-kompulzivnog poremećaja.
14. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje neuro-razvojnih poremećaja odabranih iz skupine koja se sastoji od poremećaja autističnog spektra, ADHD, cerebralne paralize, Gilles de la Tourette bolesti i neurodegenerativnih poremećaja odabranih iz skupine koja se sastoji od demencije i dobnog kognitivnog oštećenja.
15. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje stanja odabranih iz skupine koja se sastoji od poremećaja spavanja, seksualnih poremećaja, poremećaja u prehrani, gojaznosti, glavobolja i drugih bolova u uvjetima karakteriziranim povećanjem mišićnog tonusa.
16. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za poboljšanje motoričkih funkcija, kognitivnih funkcija i srodnih emocionalnih poremećaja, a nakon ozljede mozga induciran traumatskim, upalnim, infektivnim, neoplastičnim, vaskularnim, hipoksičkim ili metaboličkim uzrocima ili ozljeda mozga inducirana toksičnim reakcijama na egzogenim kemikalijama, pri čemu su egzogene kemikalije odabrane iz skupine koja se sastoji od zloupotrebe supstance, farmaceutskih spojeva, toksina okoliša.
17. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je liječenje poremećaja srodnih zloupotrebi supstance.
18. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je liječenje Alzheimerove bolesti ili srodnih poremećaja demencije.
19. Spoj prema bilo kojem zahtjevu 1-7, ili njegova farmaceutski prihvatljiva sol naznačen time, što je za uporabu kao lijek.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0502254A SE529246C2 (sv) | 2005-10-13 | 2005-10-13 | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| PCT/EP2006/009866 WO2007042295A1 (en) | 2005-10-13 | 2006-10-12 | 3, 5-disubstituted phenyl-piperidines as mdulators of dopamine? neurotransmission |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110196T1 true HRP20110196T1 (hr) | 2011-05-31 |
Family
ID=37467527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110196T HRP20110196T1 (hr) | 2005-10-13 | 2011-03-16 | 3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8501777B2 (hr) |
| EP (1) | EP1948606B1 (hr) |
| JP (1) | JP4857346B2 (hr) |
| KR (1) | KR20080046720A (hr) |
| CN (1) | CN101273014B (hr) |
| AT (1) | ATE494277T1 (hr) |
| AU (1) | AU2006301432B2 (hr) |
| BR (1) | BRPI0617355A2 (hr) |
| CA (1) | CA2625663A1 (hr) |
| DE (1) | DE602006019470D1 (hr) |
| DK (1) | DK1948606T3 (hr) |
| ES (1) | ES2358537T3 (hr) |
| HK (1) | HK1125097A1 (hr) |
| HR (1) | HRP20110196T1 (hr) |
| IL (1) | IL189298A0 (hr) |
| MY (1) | MY143241A (hr) |
| NO (1) | NO20082174L (hr) |
| NZ (1) | NZ566015A (hr) |
| PL (1) | PL1948606T3 (hr) |
| RU (1) | RU2418787C2 (hr) |
| SE (1) | SE529246C2 (hr) |
| UA (1) | UA93380C2 (hr) |
| WO (1) | WO2007042295A1 (hr) |
| ZA (1) | ZA200802238B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| US7851629B2 (en) | 2004-06-08 | 2010-12-14 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| DE602005017784D1 (de) | 2004-06-08 | 2009-12-31 | Nsab, Filial Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| PT2146961E (pt) * | 2007-04-12 | 2014-04-30 | Ivax Int Gmbh | Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados |
| CA2722978A1 (en) * | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
| EP2271635A1 (en) * | 2008-04-29 | 2011-01-12 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
| JP5548853B2 (ja) * | 2008-04-29 | 2014-07-16 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | ドーパミン神経伝達のモジュレーター |
| WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| MX2013002453A (es) | 2010-09-03 | 2013-08-01 | Ivax Int Gmbh | Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos. |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| MX2014011971A (es) | 2012-04-04 | 2015-01-16 | Ivax Int Gmbh | Composiciones farmaceuticas para terapia de combinacion. |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| AU2017315781B2 (en) | 2016-08-24 | 2021-01-28 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating dystonias |
| MX2020002645A (es) * | 2017-09-08 | 2021-06-10 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de las discinesias inducidas por fármacos. |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB850662A (en) | 1956-10-22 | 1960-10-05 | Parke Davis & Co | Substituted piperazines and processes for their production |
| BE662455A (hr) | 1964-04-14 | |||
| FR1459013A (fr) | 1964-08-05 | 1966-04-29 | Allen & Hanburys Ltd | Procédé de préparation de dérivés de la 4-phényl-pipéridine |
| GB1060160A (en) | 1964-08-05 | 1967-03-01 | Allen & Hanburys Ltd | 4-phenylpiperidine derivatives |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| ZA7546B (en) | 1974-01-21 | 1976-08-25 | Parke Davis & Co | New antibacterial amide compounds and methods for their production |
| GB1560271A (en) | 1977-01-14 | 1980-02-06 | Joullie International Sa | Therapeutically useful m-trifluoromethylphenylpiperazine derivatives |
| US4202898A (en) | 1978-06-05 | 1980-05-13 | Synthelabo | Method of treating anxiety and depression |
| FR2459797A2 (fr) | 1978-08-01 | 1981-01-16 | Synthelabo | Derives de phenyl-1 piperazine et leur application en therapeutique |
| US4333942A (en) | 1979-08-03 | 1982-06-08 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Anti-depressant and analgesic 4-phenoxypiperidines |
| US4518712A (en) | 1980-06-30 | 1985-05-21 | Taiho Pharmaceutical Company Limited | Piperazine derivative and analgesic composition containing the same |
| GB2083476B (en) | 1980-09-12 | 1984-02-08 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| FR2501506A1 (fr) | 1981-03-11 | 1982-09-17 | Sanofi Sa | Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine |
| US4415736A (en) | 1981-12-28 | 1983-11-15 | E. I. Du Pont De Nemours & Co. | Certain tetrahydropyridine intermediates |
| EP0094159B1 (en) | 1982-05-10 | 1990-03-14 | Takeda Chemical Industries, Ltd. | Dihydropyridine derivatives, their production and use |
| US4504660A (en) | 1982-07-06 | 1985-03-12 | American Home Products Corporation | Process for the production of 2,6-diaminobenzonitrile derivatives |
| HU198454B (en) | 1987-12-14 | 1989-10-30 | Richter Gedeon Vegyeszet | Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds |
| FR2639226B1 (fr) | 1988-11-18 | 1993-11-05 | Sanofi | Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| AU653837B2 (en) | 1991-04-17 | 1994-10-13 | Pharmacia & Upjohn Company | Substituted phenylazacycloalkanes as CNS agents |
| JPH06509069A (ja) | 1991-06-27 | 1994-10-13 | バージニア・コモンウェルス・ユニバーシティ | シグマレセプターリガンドおよびその用途 |
| IE914218A1 (en) | 1991-09-11 | 1993-03-24 | Mcneilab Inc | Novel 4-arylpiperazines and 4-arylpiperidines |
| EP0533268B1 (en) | 1991-09-18 | 2001-08-16 | Glaxo Group Limited | Benzanilide derivatives as 5-HT1D antagonists |
| GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| GB9119932D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| US5502050A (en) | 1993-11-29 | 1996-03-26 | Cornell Research Foundation, Inc. | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| EP0659743A1 (en) | 1993-12-27 | 1995-06-28 | Hoechst Aktiengesellschaft | Piperidine derivatives as inhibitors of platelet aggregation and their preparation |
| CA2144669A1 (en) | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
| ZA954688B (en) | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | Serotonin 5-HT1A and dopamin D2 receptor ligands |
| AU6470096A (en) | 1995-07-19 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused triazole compounds |
| US5892041A (en) | 1996-08-12 | 1999-04-06 | Neurogen Corporation | Fused indolecarboxamides: dopamine receptor subtype specific ligands |
| DE19637237A1 (de) | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazin-Derivate |
| EP0994872B9 (en) | 1997-06-10 | 2001-12-05 | Synthon B.V. | 4-phenylpiperidine compounds |
| US6232326B1 (en) | 1998-07-14 | 2001-05-15 | Jodi A. Nelson | Treatment for schizophrenia and other dopamine system dysfunctions |
| JP2000086603A (ja) | 1998-07-15 | 2000-03-28 | Yoshitomi Pharmaceut Ind Ltd | 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体 |
| IL146403A0 (en) | 1999-06-22 | 2002-07-25 | Neurosearch As | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| EP1313477A4 (en) | 2000-07-15 | 2004-03-03 | Smithkline Beecham Corp | COMPILATIONS AND METHODS |
| US7186715B2 (en) | 2001-01-08 | 2007-03-06 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| US20050004164A1 (en) | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| ATE469885T1 (de) | 2004-06-08 | 2010-06-15 | Nsab Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin- neurotransmission |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| DE602005017784D1 (de) | 2004-06-08 | 2009-12-31 | Nsab, Filial Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission |
| AU2005292134B2 (en) | 2004-10-01 | 2010-12-23 | Merck Sharp & Dohme Corp. | Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| CN101068782A (zh) * | 2004-10-13 | 2007-11-07 | 神经研究瑞典公司 | 合成4－(3－磺酰基苯基)－哌啶类的方法 |
| MX2008001152A (es) | 2005-08-05 | 2008-04-02 | Astrazeneca Ab | Benzimidazoles triciclicos y su uso como moduladores del receptor de glutamato metabotropico. |
| JP2009518337A (ja) | 2005-12-07 | 2009-05-07 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | 皮質カテコールアミン作動性神経伝達のモジュレーターとしての二置換フェニルピペリジン |
-
2005
- 2005-10-13 SE SE0502254A patent/SE529246C2/sv unknown
-
2006
- 2006-10-12 MY MYPI20081021A patent/MY143241A/en unknown
- 2006-10-12 DE DE602006019470T patent/DE602006019470D1/de active Active
- 2006-10-12 KR KR1020087008815A patent/KR20080046720A/ko active IP Right Grant
- 2006-10-12 CN CN2006800352682A patent/CN101273014B/zh not_active Expired - Fee Related
- 2006-10-12 BR BRPI0617355-1A patent/BRPI0617355A2/pt not_active IP Right Cessation
- 2006-10-12 US US12/089,412 patent/US8501777B2/en active Active
- 2006-10-12 ES ES06806224T patent/ES2358537T3/es active Active
- 2006-10-12 PL PL06806224T patent/PL1948606T3/pl unknown
- 2006-10-12 RU RU2008108618/04A patent/RU2418787C2/ru not_active IP Right Cessation
- 2006-10-12 NZ NZ566015A patent/NZ566015A/en not_active IP Right Cessation
- 2006-10-12 ZA ZA200802238A patent/ZA200802238B/xx unknown
- 2006-10-12 AT AT06806224T patent/ATE494277T1/de active
- 2006-10-12 EP EP06806224A patent/EP1948606B1/en active Active
- 2006-10-12 JP JP2008534935A patent/JP4857346B2/ja not_active Expired - Fee Related
- 2006-10-12 WO PCT/EP2006/009866 patent/WO2007042295A1/en active Application Filing
- 2006-10-12 CA CA002625663A patent/CA2625663A1/en not_active Abandoned
- 2006-10-12 AU AU2006301432A patent/AU2006301432B2/en not_active Ceased
- 2006-10-12 DK DK06806224.9T patent/DK1948606T3/da active
- 2006-12-10 UA UAA200801380A patent/UA93380C2/ru unknown
-
2008
- 2008-02-05 IL IL189298A patent/IL189298A0/en unknown
- 2008-05-09 NO NO20082174A patent/NO20082174L/no not_active Application Discontinuation
-
2009
- 2009-03-12 HK HK09102390.3A patent/HK1125097A1/xx not_active IP Right Cessation
-
2011
- 2011-03-16 HR HR20110196T patent/HRP20110196T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE529246C2 (sv) | 2007-06-12 |
| SE0502254L (sv) | 2007-04-14 |
| MY143241A (en) | 2011-04-15 |
| RU2418787C2 (ru) | 2011-05-20 |
| NZ566015A (en) | 2010-11-26 |
| JP2009511525A (ja) | 2009-03-19 |
| ATE494277T1 (de) | 2011-01-15 |
| RU2008108618A (ru) | 2009-11-20 |
| BRPI0617355A2 (pt) | 2011-07-26 |
| DE602006019470D1 (de) | 2011-02-17 |
| PL1948606T3 (pl) | 2011-08-31 |
| ZA200802238B (en) | 2009-10-28 |
| JP4857346B2 (ja) | 2012-01-18 |
| AU2006301432A1 (en) | 2007-04-19 |
| US20080234321A1 (en) | 2008-09-25 |
| AU2006301432B2 (en) | 2011-12-15 |
| ES2358537T3 (es) | 2011-05-11 |
| HK1125097A1 (en) | 2009-07-31 |
| CN101273014A (zh) | 2008-09-24 |
| UA93380C2 (en) | 2011-02-10 |
| IL189298A0 (en) | 2008-06-05 |
| EP1948606A1 (en) | 2008-07-30 |
| CN101273014B (zh) | 2011-01-12 |
| US8501777B2 (en) | 2013-08-06 |
| KR20080046720A (ko) | 2008-05-27 |
| NO20082174L (no) | 2008-07-11 |
| WO2007042295A1 (en) | 2007-04-19 |
| EP1948606B1 (en) | 2011-01-05 |
| DK1948606T3 (da) | 2011-04-04 |
| CA2625663A1 (en) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110196T1 (hr) | 3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije | |
| JP2009511525A5 (hr) | ||
| BR112015025140A2 (pt) | 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem | |
| JP2010523651A5 (hr) | ||
| BR9500996A (pt) | Derivado de difenila,agente terapêutico,processo para a preparação de um derivado de difenila,derivado de fenilpiperazina,composição farmacológica e métodos para fazer um medicamento e para tratar ou melhorar uma doença | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| JP2015523406A5 (hr) | ||
| EA201001181A1 (ru) | ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
| JP2020502092A5 (hr) | ||
| AR045659A1 (es) | Derivados de tiazolopiridina | |
| EP2604602A4 (en) | HETEROARYLPYRAZOLDERIVAT | |
| BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda | |
| MX2015002398A (es) | Benzimidazoles como agentes activos del sistema nervioso central. | |
| BRPI0409739A (pt) | composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio | |
| AR048348A1 (es) | Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos | |
| AR081908A1 (es) | N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas | |
| AR054785A1 (es) | Compuesto que comprende pirazolo (1,5-a) pirimidinas halogenadas, procedimiento para prepararlo uso de dicho compuesto composicion farmaceutica que lo comprende, procedimiento para preparar sus intermedios y compuesto intermedio | |
| NZ588209A (en) | 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives for the modulation of dopaminergic function in the central nervous system | |
| ATE367163T1 (de) | 4-(sulfanylpyrimidin-4-ylmethyl)morpholin- derivate und verwandte verbindungen als gaba- rezeptorliganden zur behandlung von angst, depression und epilepsie | |
| AR079103A1 (es) | Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion | |
| CL2011000520A1 (es) | Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos. | |
| RU2020127537A (ru) | Соединения, которые модулируют функцию ampa-рецептора | |
| JP2012509860A5 (hr) | ||
| FI3541784T3 (fi) | Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina |